Is Pitobrutinib/Jepali a targeted drug?

Pirtobrutinib/Jepali (Pirtobrutinib) is a typical targeted drug. The so-called targeted drugs refer to inhibiting tumor development by identifying and interfering with specific molecular pathways. Unlike traditional chemotherapy"broad-spectrum attack", targeted drugs are more precise and efficient, and have relatively low side effects. Pitobrutinib, as a BTK inhibitor, precisely binds to Bruton's tyrosine kinase (BTK), a key molecule in the B cell signaling pathway, blocking its abnormal activation, thereby inhibiting the malignant proliferation of B cells. This mechanism determines that it belongs to the category of molecular targeted drugs.

Compared with the first and second generation BTK inhibitorsPitobrutinib has several important features: First, it is a non-covalent inhibitor that can maintain binding force even after the BTK protein is mutated, so it is still effective in drug-resistant patients; second, Pitobrutinib is more selective and can reduce non-specific inhibition of other tyrosine kinases, thereby reducing the risk of adverse reactions. These advantages not only prove its targeting, but also make it widely regarded as an "upgraded version" of BTK inhibitors in clinical practice.

As a targeted drug, pitubrutinib has outstanding clinical application value. It is mainly used to treat chronic lymphocytic leukemia (CLL), mantle cell lymphoma and other B-cell malignancies. It is especially suitable for patients who have developed drug resistance or relapse after using other BTK inhibitors in the past. Its targeting mechanism makes drug effects more predictable and patients can achieve longer disease control periods.

Currently, domestic and foreign guidelines are gradually incorporating pitubrutinib into treatment recommendations, especially for complex and refractory cases. As more research results are released in the future, its indications may be further expanded. To sum up, pitubrutinib is not only a targeted drug, but also represents a new direction in the development of BTK inhibitors, opening up a new path for the treatment of hematological tumors.

Reference materials:https://go.drugbank.com/drugs/DB17472